Q2 2026 newsletter – PROTAC MetID focus
From tackling the metabolism of PROTACs to synthesising oxidised metabolites, our latest newsletter features a MetID study undertaken at Hypha using the tool PROTAC MZ1, together with possible routes to accessing key metabolites.
💡 Highlights
- MZ1 MetID case study across multiple species
- Integrated LC-MS/MS + synthesis screening approach with PolyCYPs and PolyUGTs
- New publication with AstraZeneca on a tricky-to-synthesise N-glucuronide of camizestrant, and a paper by Merck KGaA on a major hydroxylated metabolite of xevinapant
- On-demand MetID webinar link now available on request. In this webinar held last month we discussed how Hypha uniquely integrates LC-MS/MS-based MetID with scalable metabolite synthesis and definitive structure confirmation by NMR spectroscopy. This enables metabolites to be made, identified and tested early on.
We can tailor MetID and metabolite synthesis packages to your requirements.
📩 Get in touch to learn more or access the webinar recording.
